JP2016520583A - パッパリシンレギュレーター - Google Patents

パッパリシンレギュレーター Download PDF

Info

Publication number
JP2016520583A
JP2016520583A JP2016512227A JP2016512227A JP2016520583A JP 2016520583 A JP2016520583 A JP 2016520583A JP 2016512227 A JP2016512227 A JP 2016512227A JP 2016512227 A JP2016512227 A JP 2016512227A JP 2016520583 A JP2016520583 A JP 2016520583A
Authority
JP
Japan
Prior art keywords
stanniocalcin
pappalysin
polypeptide
papp
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520583A5 (https=
Inventor
オックスヴィグ，クラウス
ハウゲ ミッケルセン，ジェイコブ
ハウゲ ミッケルセン，ジェイコブ
ルンゲ ジェプセン，マレン
ルンゲ ジェプセン，マレン
Original Assignee
オルフス ユニバーシテト
オルフス ユニバーシテト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オルフス ユニバーシテト, オルフス ユニバーシテト filed Critical オルフス ユニバーシテト
Publication of JP2016520583A publication Critical patent/JP2016520583A/ja
Publication of JP2016520583A5 publication Critical patent/JP2016520583A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24079—Pappalysin-1 (3.4.24.79)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016512227A 2013-05-10 2014-05-12 パッパリシンレギュレーター Pending JP2016520583A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201370259 2013-05-10
DKPA201370259 2013-05-10
PCT/DK2014/050131 WO2014180485A2 (en) 2013-05-10 2014-05-12 Pappalysin regulator

Publications (2)

Publication Number Publication Date
JP2016520583A true JP2016520583A (ja) 2016-07-14
JP2016520583A5 JP2016520583A5 (https=) 2017-06-15

Family

ID=50943008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512227A Pending JP2016520583A (ja) 2013-05-10 2014-05-12 パッパリシンレギュレーター

Country Status (9)

Country Link
US (2) US20160151405A1 (https=)
EP (1) EP2994158A2 (https=)
JP (1) JP2016520583A (https=)
CN (1) CN105263510A (https=)
CA (1) CA2911933A1 (https=)
EA (1) EA201591894A1 (https=)
HK (1) HK1215929A1 (https=)
MX (1) MX2015015519A (https=)
WO (1) WO2014180485A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022004054A1 (https=) * 2020-06-30 2022-01-06

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202235618A (zh) * 2021-01-05 2022-09-16 美國馬友醫藥教育研究基金會 治療眼內壓相關疾患
WO2022270926A1 (ko) * 2021-06-22 2022-12-29 동아대학교 산학협력단 다양한 암의 진단, 전이 또는 예후 예측용 신규한 바이오마커 및 이의 용도
WO2024042220A1 (en) * 2022-08-25 2024-02-29 Aarhus Universitet Modulators of papp-a activity
TW202432584A (zh) 2022-11-15 2024-08-16 美商嘉來克生命科學有限責任公司 抗papp-a抗體及其使用方法
WO2026008015A1 (en) * 2024-07-05 2026-01-08 The University Of Hong Kong Stanniocalcin 2 (stc2) and derivatives as anti-diabetic agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030969A2 (en) * 1999-10-27 2001-05-03 Human Genome Sciences, Inc. Stanniocalcin proteins and nucleic acids and methods based thereon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994103A (en) * 1995-06-02 1999-11-30 Human Genome Science, Inc. Human stanniocalcin-alpha
CA2389751A1 (en) 1999-11-01 2001-05-10 Curagen Corporation Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
WO2005035732A2 (en) 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
US20100292303A1 (en) 2007-07-20 2010-11-18 Birrer Michael J Gene expression profile for predicting ovarian cancer patient survival
AU2009207645B2 (en) 2008-01-25 2014-11-13 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
WO2010020004A1 (en) * 2008-08-22 2010-02-25 Children's Medical Research Institute Compositions and methods for inhibition of adipogenesis and the treatment of obesity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030969A2 (en) * 1999-10-27 2001-05-03 Human Genome Sciences, Inc. Stanniocalcin proteins and nucleic acids and methods based thereon

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022004054A1 (https=) * 2020-06-30 2022-01-06
JP7702150B2 (ja) 2020-06-30 2025-07-03 国立大学法人東北大学 Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤

Also Published As

Publication number Publication date
HK1215929A1 (zh) 2016-09-30
WO2014180485A3 (en) 2015-03-05
US20200261490A1 (en) 2020-08-20
EP2994158A2 (en) 2016-03-16
WO2014180485A2 (en) 2014-11-13
US20160151405A1 (en) 2016-06-02
MX2015015519A (es) 2016-07-21
US11318158B2 (en) 2022-05-03
CN105263510A (zh) 2016-01-20
CA2911933A1 (en) 2014-11-13
EA201591894A1 (ru) 2016-04-29

Similar Documents

Publication Publication Date Title
US11318158B2 (en) Pappalysin regulator
US20200384106A1 (en) Novel anti-human gpvi antibodies and uses thereof
US8044179B2 (en) Methods and compositions for modulating tumor cell activity
JP7487938B2 (ja) 抗ｃｄ５ｌ抗体及びその使用
EA025218B1 (ru) Способ диагностики злокачественных новообразований, экспрессирующих рецептор her2 или его укороченные варианты
CN114641497B (zh) 抗bdca-2抗体
TWI826934B (zh) 新穎抗ｐａｄ４抗體
CN102482348B (zh) 胶原新表位抗体
CN107098970A (zh) 结合细胞内prl‑1多肽或prl‑3多肽的抗体
CN102099376A (zh) 针对her2的细胞外结构域2和3的抗体
CN107074963B (zh) 抑制血管内皮脂肪酶的酶活性的人源化单克隆抗体
RU2770006C2 (ru) Антитела к фактору ix padua
EP1978034B1 (en) Anti-periostin antibody and pharmaceutical composition containing the same for preventing or treating periostin-related disease
JP2016000713A (ja) 線維芽細胞増殖因子４に対するハイブリドーマクローンおよびモノクローナル抗体
JP2010512781A (ja) Ｖｅｇｆｒの変化体ならびに妊娠関連の医学的状態の診断および処置におけるその使用
CN101522715B (zh) 针对可溶型lox-1的单克隆抗体
WO2009101968A1 (ja) 抗ａｄａｍ－１５抗体及びその利用
Hamaoka et al. Anti-human HB-EGF monoclonal antibodies inhibiting ectodomain shedding of HB-EGF and diphtheria toxin binding
US20100173314A1 (en) Diagnostic methods using tenascin-w compositions
US9701744B2 (en) Anti-Vasohibin 2 antibody
US20050004003A1 (en) Substance which inhibits binding of information transfer molecule for 1175-tyrosine phosphorylated KDR/Flk-1 and usages of the same
CN107407681B (zh) 胰功能异常的检测方法和检测用试剂盒
US20250206846A1 (en) Anti-klk4 antibodies and uses thereof
EP1338655A1 (en) Substance inhibiting the binding of signal transducing molecule to kdr/flk-1 phosphorylated at tyrosine at the 1175-position and method of using the same
JP2018154608A (ja) 抗ａｄａｍタンパク質基質抗体及びその利用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180911